Generic Name |
Pazopanib + vorinostat | |
---|---|---|
IND |
||
Brand Name (US) |
Votrient + Zolinza | |
Manufacturer |
GlaxoSmithKline & Merck | |
Drug Type |
Tyrosine Kinase Inhibitor + HDAC inhibitor | |
Delivery |
Oral | |
Approval Status |
Both are approved for non-GIST applications | |
Indications |
Kidney cancer, CTCL | |
Overall Strategy |
KIT Protein + GIST cell based | |
Strategy |
Block KIT + Destroy KIT | |
Drug Category |
KIT/PDGFRA inhibitor + HDAC inhibitor |
Pazopanib is a potent VEGFR inhibitor but it also inhibits KIT and PDGFRs. It is entering a phase II trial for GIST (~spring 2011).
Vorinostat is a HDAC inhibitor. This class of drugs have multiple modes of activity including inhibition of HSP90 which may result in destruction of the KIT protein.
Links |
|
Trials of this drug |
|
|
Phase I Study of Pazopanib and Vorinostat |
Trial results |